Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Current Liabilities (2018 - 2025)

Serina Therapeutics' Total Current Liabilities history spans 8 years, with the latest figure at $2.4 million for Q1 2025.

  • For Q1 2025, Total Current Liabilities fell 83.27% year-over-year to $2.4 million; the TTM value through Mar 2025 reached $2.4 million, down 83.27%, while the annual FY2023 figure was $1.4 million, 85.98% down from the prior year.
  • Total Current Liabilities for Q1 2025 was $2.4 million at Serina Therapeutics, down from $12.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $24.5 million in Q2 2023 and bottomed at $1.4 million in Q4 2023.
  • The 5-year median for Total Current Liabilities is $9.0 million (2021), against an average of $10.0 million.
  • The largest YoY upside for Total Current Liabilities was 169.73% in 2023 against a maximum downside of 85.98% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $9.0 million in 2021, then rose by 12.39% to $10.1 million in 2022, then crashed by 85.98% to $1.4 million in 2023, then soared by 794.06% to $12.6 million in 2024, then crashed by 81.38% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Total Current Liabilities are $2.4 million (Q1 2025), $12.6 million (Q2 2024), and $14.1 million (Q1 2024).